Trials / Completed
CompletedNCT03071848
A Study to Evaluate Safety and Effectiveness of Bevacizumab in Combination With Paclitaxel and Cisplatin/Carboplatin or Toptecan in Participants With Advanced Cervical Cancer
Retrospective Multicenter Observational Study to Evaluate Safety and Effectiveness of Bevacizumab (Avastin®) in Combination With Paclitaxel and Cisplatin/Carboplatin or Toptecan in Patients With Advanced Cervical Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 84 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety of bevacizumab (Avastin®) combined with standard chemotherapy in participant with advanced cervical cancer, with special focus on the incidence of gastrointestinal (GI) and genitourinary (GU) fistulas and GI perforations in the common practice setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No Intervention | This was an observational study. |
Timeline
- Start date
- 2017-04-06
- Primary completion
- 2017-12-20
- Completion
- 2017-12-20
- First posted
- 2017-03-07
- Last updated
- 2018-03-16
Locations
12 sites across 1 country: Argentina
Source: ClinicalTrials.gov record NCT03071848. Inclusion in this directory is not an endorsement.